APEPTICO Announces Successful Completion of Phase I Trial with AP301 in Oedematous Respiratory ...
Vienna, Austria, October 25, 2011 / B3C newswire / - APEPTICO GmbH , a biotechnology company developing peptide drugs based on its PEPBASE™ discovery technology, today announced completion of a Phase I clinical trial for its pulmonary sodium ion channel …